Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.260
+0.070 (3.20%)
At close: Oct 15, 2026, 4:00 PM EDT
2.230
-0.030 (-1.33%)
After-hours: Oct 15, 2026, 7:33 PM EDT
Ovid Therapeutics Revenue
Ovid Therapeutics had revenue of $733.00K in the quarter ending June 30, 2026, a decrease of -88.31%. This brings the company's revenue in the last twelve months to $1.58M, down -76.20% year-over-year. In the year 2025, Ovid Therapeutics had annual revenue of $7.25M with 1,181.27% growth. That makes Ovid Therapeutics the 42,796th largest company in the world by revenue and 5,881st in the United States.
Revenue (ttm)
$1.58M
Revenue Growth
-76.20%
P/S Ratio
278.82
Revenue / Employee
$68,826
Employees
23
Market Cap
441.37M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.25M | 6.69M | 1,181.27% |
| Dec 31, 2024 | 566.00K | 174.00K | 44.39% |
| Dec 31, 2023 | 392.00K | -1.11M | -73.91% |
| Dec 31, 2022 | 1.50M | -206.88M | -99.28% |
| Dec 31, 2021 | 208.38M | 195.77M | 1,551.57% |
| Dec 31, 2020 | 12.62M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 316.70M |
| Autolus Therapeutics | 117.39M |
| Assembly Biosciences | 74.85M |
| Allogene Therapeutics | 4.64M |
| Oculis Holding AG | 1.45M |
| YD Bio | 1.24M |
| Neurogene | 925.00K |
| Entera Bio | 42.00K |
OVID News
- 17 hours ago - Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer - PRNewsWire
- 18 hours ago - Ovid Therapeutics initiated with an Outperform at Wolfe Research - TheFly
- 6 days ago - Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 6 days ago - Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 9 days ago - Ovid Therapeutics management to meet with B. Riley - TheFly
- 10 days ago - Guggenheim starts Ovid Therapeutics with a Buy on OV329 potential - TheFly
- 10 days ago - Ovid Therapeutics initiated with a Buy at Guggenheim - TheFly
- 4 weeks ago - Ovid Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts